{"id":"high-dose-ultra-short-primaquine","safety":{"commonSideEffects":[{"rate":null,"effect":"Hemolysis (in G6PD-deficient patients)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Methemoglobinemia"}]},"_chembl":{"chemblId":"CHEMBL455150","moleculeType":"Small molecule","molecularWeight":"404.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Primaquine is an 8-aminoquinoline antimalarial that works by generating reactive oxygen species within malaria parasites, causing oxidative damage to parasite DNA and cellular structures. The high-dose ultra-short regimen aims to achieve rapid parasite clearance and gametocyte elimination while minimizing treatment duration, thereby reducing transmission potential and improving patient compliance.","oneSentence":"High-dose ultra-short primaquine rapidly eliminates malaria parasites, particularly gametocytes, to prevent transmission and treat infection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:41:46.627Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Malaria treatment and transmission prevention"},{"name":"Plasmodium vivax and Plasmodium ovale hypnozoite elimination"}]},"trialDetails":[{"nctId":"NCT07468526","phase":"PHASE3","title":"An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria","status":"NOT_YET_RECRUITING","sponsor":"Menzies School of Health Research","startDate":"2026-06-01","conditions":"Malaria","enrollment":1019}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"High dose ultra short Primaquine","genericName":"High dose ultra short Primaquine","companyName":"Menzies School of Health Research","companyId":"menzies-school-of-health-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"High-dose ultra-short primaquine rapidly eliminates malaria parasites, particularly gametocytes, to prevent transmission and treat infection. Used for Malaria treatment and transmission prevention, Plasmodium vivax and Plasmodium ovale hypnozoite elimination.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}